linjc16/ctgov huggingface dataset:
68Ga-labeled NY104 PET Imaging in Patients

Study Overview
=================
Brief Summary
-----------------
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY104 PET Imaging in patients with Renal Cell Carcinoma

Official Title
-----------------
68Ga-labeled NY104 PET Imaging in Patients

Conditions
-----------------
Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Drug: 68Ga-NY104


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients voluntarily signed informed consent; Age 18-75, male or female; Patients diagnosed with renal cell carcinoma confirmed by histopathology or cytology; At least one measurable solid lesion has been examined according RECIST1.1 standard; ECOG score 0 3; Life expectancy of at least 3 months; Exclusion Criteria: Recovery from major trauma (including surgery) within 4 weeks prior to study treatment; Patients with systemic or locally severe infections, or other serious coexisting diseases; Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; Patients with autoimmune diseases, including rheumatoid arthritis; Inadequate control of arrhythmias, including atrial fibrillation; Uncontrolled hypertension; Patients with allergies or allergies to any component of the imaging agent or antibody; Patients who cannot undergo PET/CT imaging scan; Syphilis, HBV, HCV, or HIV positive subjects; Male and female subjects of reproductive age cannot take effective contraceptive measures; Pregnant or lactating women; Patients with a history of mental illness or related conditions; Other subjects considered unsuitable by researchers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 68Ga-NY104<br> | Drug: 68Ga-NY104<br>* Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of tissue distribution of 68Ga-NY104 | Biodistribution of 68Ga-NY104 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 68Ga-PET scans will be reported. | 1 year |
Pancreatic Duodenal Homeobox Factor-1 (PDX-1) and Neurogenin-3 (NGN-3) in Gestational Diabetes

Study Overview
=================
Brief Summary
-----------------
Introduction: Depletion of the ability of the cells ß to secrete the amount of insulin required by pregnancy, increasing the risk of develop Gestational Diabetes Mellitus (GDM). The aim was to contrast the messenger RNA (mRNA) expression of the pancreatic duodenal homeobox factor-1 (PDX-1) and Neurogenin-3 (Ngn-3) in peripheral blood of pregnant women with GDM versus women with normal pregnancies. Material and methods: This was a prospective, clinical and cross-sectional study, conforming two groups of pregnant women: a) patients with a healthy gestation and b) patients with GDM. Besides anthropometry and routine laboratorial test, real-time polymerase chain reaction (Real-Time PCR), was used to quantify the expression of PDX-1 and NGN-3.

Detailed Description
-----------------
Pregnant women attended in the Maternal-Fetal Medicine Service of the Mónica Pretelini Sáenz Maternal-Perinatal Hospital, were invited to participate. Those with autoimmune diseases, heart disease, nephropathy, liver disease or any other chronic condition were excluded and those with incomplete clinical files were discarded from the final analysis. Two groups were integrated: a) patients with a healthy gestation and b) patients with GDM. From all patients the next information was captured in an excell sheet: weight, height, Body Mass Index, blood pressure, albumin, creatinine, electrolytes, glucose, total cholesterol, triglycerides, transaminases and relative expression of PDX-1 and NGN-3.

Official Title
-----------------
PDX-1 and NGN-3 Expression in Gestational Diabetes

Conditions
-----------------
Gestational Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women older than 18 years old. Exclusion Criteria: Those with autoimmune diseases, heart disease, nephropathy, liver disease or any other chronic condition.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Women with normoevolutionary gestation. | |
| Problem group<br>Patients with GDM. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ARNm expression | Expression of the genes PDX-1 and NGN-3 | Nine months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PDX-1, NGN-3, Glucose
Improving Teamwork in an Academic, Tertiary Care Labor and Delivery Unit

Study Overview
=================
Brief Summary
-----------------
The investigators wanted to determine if the establishment of interdisciplinary rounds has made meaningful changes in the perceptions of teamwork and communication. The purpose of this study is to determine if the establishment of interdisciplinary daily rounding has improved teamwork in an academic, tertiary care labor and delivery unit.

Detailed Description
-----------------
Failures in teamwork and communication are among the leading cases of sentinel and adverse obstetric events. Multidisciplinary approaches and communication could improve patients outcomes. In 2003, leaders from the department of obstetrics, anesthesia and nursing decided to institute interdisciplinary rounds as a method of improving team communication. Obstetricians, Anesthesiologists, Nurses, Perinatologists, Administrative Assistants, Consultants, and Neonatologists participate in the rounds. The investigators wanted to determine if the establishment of interdisciplinary rounds has made meaningful changes in the perceptions of teamwork and communication. The purpose of this study is to determine if the establishment of interdisciplinary daily rounding has improved teamwork in an academic, tertiary care labor and delivery unit.

Official Title
-----------------
A Decade of Safon Rounds: Interdisciplinary Daily Rounding as a Method of Improving Teamwork in an Academic, Tertiary Care Labor and Delivery Unit

Conditions
-----------------
Interdisciplinary Communication

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Working at L&D at Brigham and Women's and participating in daily rounds Exclusion Criteria: subject's refusal to participate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|25-item questionnaire on pereception of interdisciplinary rounds|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perception of Teamwork Elements Present in Interdisciplinary Rounds - Total Response Scores |  | Individual Participation-10 min; Study Completion within 1 Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
teamwork
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma

Official Title
-----------------
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Conditions
-----------------
Esophageal Squamous Cell Carcinoma

Intervention / Treatment
-----------------
* Drug: Camrelizumab
* Drug: Paclitaxel for Injection (Albumin Bound)
* Drug: Carboplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological diagnosis of thoracic Esophageal squamous cell carcinoma ECOG performance status 0-1 Age 18-75 years Resectable disease, cT2-4aNanyM0 or cT1-3N+M0 Life expectancy more than 6 months Use of an effective contraceptive for adults to prevent pregnancy Exclusion Criteria: Not suitable for surgery Prior chemotherapy, radiotherapy and immune-oncology therapies for ESCC Prior esophageal, gastric, or gastro-esophageal junction surgery Esophageal ulcer, esophageal perforation，chest pain（≥middle level） Pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Camrelizumab plus Chemotherapy<br> | Drug: Camrelizumab<br>* Camrelizumab 200mg D1, D22<br>Drug: Paclitaxel for Injection (Albumin Bound)<br>* Paclitaxel for Injection (Albumin Bound) 100mg/m^2 D1, D8, D22, D29<br>Drug: Carboplatin<br>* Carboplatin AUC5 D1, D22<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathologic complete remission (PCR) |  | 12 weeks | 
| Major Pathologic Response (MPR) |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival (OS) |  | 5 years | 
| Event Free Survival（EFS） |  | 5 years |
Effect of Progesterone Therapy on Traumatic Subarachinoid Haemorrhage on Clinical Outcome and Resistive Vasculer Indices of Middle Cerebral Artery Transcranial Doppler

Study Overview
=================
Brief Summary
-----------------
Traumatic subarachinoid hemorrhage is associated with serious complications related to mortality . Delayed neuronal ischemia and rebleeding are most common and serious. Progesterone can delay both .

Detailed Description
-----------------
Progesterone is an neurosteroid that can help integrity of blood brain barrier . Traumatic subarachinoid hemorrhage disrupts this blood brain barrier facilitating post traumatic vasospasm and neuronal ischemia. Transcranial doppler can detect cerebral vasoconstriction through resistive vasculer indices

Official Title
-----------------
Effect of Progesterone Therapy in Cases With Traumatic Subarachinoid Haemorrhage on Clinical Outcome and Resistive Vasculer Indices of Middle Cerebral Artery Transcranial Doppler

Conditions
-----------------
Traumatic Brain Injury

Intervention / Treatment
-----------------
* Drug: Progesterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Traumatic subarachinoid hemorrhage Exclusion Criteria: History of malignency History of cerebrovasculer stroke Morbid obese

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control<br>Receiving conventional management for traumatic subarachinoid hemorrhage | Drug: Progesterone<br>* Intramusculer progesterone<br>|
| Active Comparator: progesterone group<br>Intramusculer progesterone therapy before and after craniotomy | Drug: Progesterone<br>* Intramusculer progesterone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants suffering neuronal infarction | Transcranial doppler | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Progesterone, Transcranial doppler
Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21

Study Overview
=================
Brief Summary
-----------------
This is a study for the evaluation of the benefits of 1 st Trimester risk markers in detecting Early Onset Pre-eclampsia and the use of the Placental Growth factor(PIGF) as a potential marker for Trisomy 21 and other aneuploidies. Aim of this prospective nonprofit study is to analyze the benefits of early onset pre eclampsia risk assessment in the 1st trimester (measuring biochemical markers [PIGF], blood pressure and Doppler ultrasound), and how the results can permit to modify or influence the course of the preeclampsia during the pregnancy. The investigators will also evaluate the potential use of the PIGF as a marker to improve the prenatal screening with the currently used nuchal translucency, serum Pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (fBhCG) parameters.

Official Title
-----------------
Study for the Evaluation of the Benefits of 1 st Trimester Risk Markers in Detecting Early Onset Pre-eclampsia and the Use of the Placental Growth Factor (PlGF) as a Potential Marker for Trisomy 21 and Other Aneuploidies

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton pregnancy Nulliparous pregnancy Gestation age between 6.0-13.6 weeks by last menstrual period verified by ultrasound Blood sample provided at gestational age 6.0-13.6 weeks Informed Consent Exclusion Criteria: Multi-fetal pregnancy Primiparous or multiparous pregnancy Mental retardation or other mental disorders that impose doubts regarding the true patient's willingness to participate in the study Gestation age below 6.0 or above 13.6 weeks by last menstrual period verified by ultrasound. Lack of blood sample at the specified enrollment period Known major fetal anomaly or fetal demise Lack of demographic data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| study group<br>patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| levels of Placental Protein 13 (PP13) , PIGF, PAPP-A, PIBF | levels of PP13, PIGF, PAPP-A will de considered in association with Doppler ultrasound and standardised blood pressure measurements to see if they can be used as early risk markers in patients having a delivery before 34 weeks gestation | 6-13.6 wks gestation |
Registry for Chronic Venous Disease Incidence and Natural Course

Study Overview
=================
Brief Summary
-----------------
A prospective cohort study of patients with primary varicose veins to assess the morbidity, risk factors and development of chronic lower limb vein disease.

Detailed Description
-----------------
Multicenter prospective cohort observational study based on a termless epidemiological registry. Periodic inspection and collection of data from the subjects is carried out annually, in the last quarter of the current year. Patient data is recorded in a promising digital database and is constantly updated.

Official Title
-----------------
Russian Registry for Chronic Venous Disease Incidence and Natural Course

Conditions
-----------------
Varicose Veins of Lower Limb

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A family members of the researcher (spouse, childrens, brothers and sisters, parents) or the researcher himself The possibility of annual clinical and ultrasound assessment of the venous system of the observed individuals Exclusion Criteria: Any invasive treatment of the chronic venous disorder in anamnesis Venous thrombosis in the anamnesis or at the time of inclusion

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients without Chronic Venous Disease<br>Individuals who do not have signs of chronic venous diseases of lower legs according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP) | |
| Patients with Chronic Veinous Disease<br>Individuals who have signs of chronic venous diseases of lower legs according to CEAP classification (telangiectases, varicose veins, venous edema, skin hyperpigmentation, lipodermatosclerosis, venous ulcer). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Chronic Venous Disease | Number of Participants with the first identified signs of chronic venous disease according to CEAP classification (telangiectasia, varicose veins, edema) | 1 year | 
| Natural Course of Chronic Venous Disease | Progression of CVD will be measured as a change in clinical class of CVD according to CEAP classification in every individual affected by CVD | 1 year | 
| Incidence of chronic venous insufficiency | Number of Participants with the first identified sign of chronic venous insufficiency (venous edema, venous eczema, hyperpigmentation of the skin, lipodermatosclerosis, venous ulcer) | 1 year | 
| Incidence of superficial vein thrombosis | Number of Participants with the first identified sign of superficial vein thrombosis | 1 year |
Immune Status in Solid Organ Transplantation

Study Overview
=================
Brief Summary
-----------------
Immunosuppressive therapy protocols in solid organ transplantation are rudimentary, differ by transplant center and no practical strategies are available to guide an individuals' response to immune suppression. In this study we will conduct research to assess immunologic status in solid organ transplant recipients, predicting immune reconstitution and outcomes after transplant to better guide the use of immunosuppressive medications.

Official Title
-----------------
Evaluation of Predictors of Immune Status in Solid Organ Transplantation

Conditions
-----------------
Organ Transplants

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Impending kidney transplant Age >18 Able to provide informed consent and comply with the study procedures Exclusion Criteria: Age<18 Concomitant illness, which by decision of investigator, may compromise the ability to perform this trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Organ transplant recipients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune Markers |  | 0, 3, 6, 9, 12 months |
Validation of a Food Addiction Screening Test

Study Overview
=================
Brief Summary
-----------------
Food addiction (FA) is a behavioral addiction characterized by a high consumption of palatable foods, which markedly activate the reward system, despite adverse consequences. FA was first described in 1956 but remains controversial. The Yale Food Addiction Scale (YFAS), developed by Gearhardt et al. in 2009, is currently regarded as the Gold Standard for FA screening. In a previous study, we established a Food Addiction Screening Test using artificial intelligence. The main objective of the present study is to validate the sensitivity, specificity and precision for FA diagnosis in a sample of patient suffering from obesity and healthy volunteers.

Official Title
-----------------
Validation Study of a Rapid Screening Test of Food Addiction in Patients Suffering From Obesity and Healthy Volunteer

Conditions
-----------------
Food Addiction, Obesity

Intervention / Treatment
-----------------
* Other: Online survey - questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI ≥ 30 Able to consent Exclusion Criteria: Non-french speaker Patient unable to use internet tools

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participant suffering from obesity<br>Patient, male or female, over 18 and under 70 years old Patient group with a Body Mass Index (BMI) greater than or equal to 30 kg / m2 | Other: Online survey - questionnaire<br>* Online survey - questionnaire<br>|
| healthy volunteer<br> | Other: Online survey - questionnaire<br>* Online survey - questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FAST score | Screening test to validate | Baseline | 
| YFAS 2.0 | Screening test to validate DSM-5 Yale Food Addiction Scale (YFAS 2.0) | Baseline | 
| BES score | Binge Eating Scale scoring | Baseline | 
| DEBQ score | Dutch Eating Behaviour Questionnaire scoring | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
food Addiction, Obesity